

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Ibrutinib

March 17, 2026

Therapeutic category

Other antitumor agents

Non-proprietary name

Ibrutinib

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Ketoconazole, itraconazole, clarithromycin, ensitrelvir fumaric acid			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Ketoconazole, itraconazole, clarithromycin, ensitrelvir fumaric acid, <u>ceritinib</u>		
10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)			10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Ketoconazole (oral dosage form; not marketed in Japan) Itraconazole Clarithromycin Ensitrelvir fumaric acid	The blood concentration of this drug may rise, and adverse reactions may be enhanced.	The metabolism of this drug is suppressed due to CYP3A inhibition by these drugs.	Ketoconazole (oral dosage form; not marketed in Japan) Itraconazole Clarithromycin Ensitrelvir fumaric acid <u>Ceritinib</u>	The blood concentration of this drug may rise, and adverse reactions may be enhanced.	The metabolism of this drug is suppressed due to CYP3A inhibition by these drugs.